Grimm, Oliver http://orcid.org/0000-0002-0767-0301
van Rooij, Daan
Tshagharyan, Asya
Yildiz, Dilek
Leonards, Jan
Elgohary, Ahmed
Buitelaar, Jan http://orcid.org/0000-0001-8288-7757
Reif, Andreas http://orcid.org/0000-0002-0992-634X
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (445498183)
EC | Horizon 2020 Framework Programme (667302, 667302, 667302, 667302, 667302, 667302, 667302, 667302)
Article History
Received: 29 July 2021
Revised: 18 November 2021
Accepted: 30 November 2021
First Online: 16 December 2021
Competing interests
: Andreas Reif received personal fees from MEDICE Arzneimittel Pütter GmbH & Co. KG, Shire PLC, neuraxpharm Arzneimittel GmbH, Janssen‐Cilag GmbH and Servier Deutschland GmbH present or during 36 months prior to publication. Jan K. Buitelaar has been in the past 3 years a consultant to / member of the advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Oliver Grimm received personal fees from MEDICE Arzneimittel Pütter GmbH & Co. KG. The other authors did not have any competing interests.